Article Text

Original research
Preliminary in vivo evaluation of a novel intrasaccular cerebral aneurysm occlusion device
  1. Roham Moftakhar1,
  2. Fangmin Xu2,
  3. Beverly Aagaard-Kienitz3,
  4. Daniel W Consigny3,
  5. Julie R Grinde3,
  6. Kevin Hart4,
  7. Claire E Flanagan2,
  8. Wendy C Crone2,4,
  9. Kristyn S Masters2
  1. 1Department of Neurological Surgery, Rush University Medical Center, Chicago, Illinois, USA
  2. 2Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA
  3. 3Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA
  4. 4Department of Engineering Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA
  1. Correspondence to Dr R Moftakhar, Department of Neurological Surgery, Rush University Medical Center, Chicago, IL 60612, USA; roham.moftakhar{at}


Objective Current endovascular technology does not offer a perfect solution for all cerebral aneurysms. Our group has built two versions of a novel aneurysm intrasaccular occlusion device (AIOD) to address the drawbacks associated with current occlusion devices. The objective of the present study was to perform pilot proof of concept in vivo testing of this new AIOD in swine and canines.

Methods Two configurations of the AIOD, termed ‘coil-in-shell’ and ‘gel-in-shell’, were implanted in surgically created sidewall aneurysms (n=4) in swine for acute occlusion studies, as well as sidewall (n=8) and bifurcation aneurysms (n=3) in canines to assess long term occlusion efficacy. Occlusion at all time points (immediate, 6 weeks, and 12 weeks) was evaluated by angiography. Neointimal healing at 12 weeks post-implantation in canines was examined histologically.

Results Angiographic analysis showed that both the coil-in-shell and gel-in-shell devices achieved complete aneurysm occlusion immediately following device delivery in sidewall aneurysms in swine. In longer term canine studies, initial occlusion ranged from 71.3% to 100%, which was stable with no recurrence in any of the sidewall aneurysms at 6 or 12 weeks. Histological analysis at 12 weeks showed mature fibromuscular tissue at the neck of all aneurysms and no significant inflammatory response.

Conclusions The AIOD tested in this study showed promise in terms of acute and chronic occlusion of aneurysms. Our findings suggest that these devices have the potential to promote robust tissue healing at the aneurysm neck, which may minimize aneurysm recurrence. Although proof of principle has been shown, further work is needed to deliver this device through an endovascular route.

  • Aneurysm
  • Bioactive
  • Device
  • Liquid Embolic Material

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement: